Article
Rheumatology
Siddharth Jain, Varun Dhir, Amita Aggarwal, Ranjan Gupta, Bidyalaxmi Leishangthem, Shankar Naidu, Aastha Khullar, Supriya Maurya, Veena Dhawan, Shefali Khanna Sharma, Aman Sharma, Sanjay Jain
Summary: This study compared the efficacy and safety of different dose escalation strategies of oral MTX in RA patients over a period of 16-24 weeks. The results showed that a faster escalation strategy was not more effective than the usual strategy, but was associated with higher gastrointestinal adverse events in the initial phase.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Oncology
Milind Javle, Mitesh J. Borad, Nilofer S. Azad, Razelle Kurzrock, Ghassan K. Abou-Alfa, Ben George, John Hainsworth, Funda Meric-Bernstam, Charles Swanton, Christopher J. Sweeney, Claire F. Friedman, Ron Bose, David R. Spigel, Yong Wang, Jonathan Levy, Katja Schulze, Vaikunth Cuchelkar, Arisha Patel, Howard Burris
Summary: The study evaluated the activity of pertuzumab plus trastuzumab in patients with HER2-positive metastatic biliary tract cancer. The results showed a promising response rate and good tolerability, suggesting the need for further randomized, controlled trials in this patient population.
Article
Hematology
Jorge Cortes, Jane Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, Charles A. Schiffer, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Christine Rojas, Christopher Kevin Arthur, Lori Maness, Moshe Talpaz, Michael Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael Deininger
Summary: The study focused on the treatment of CP-CML patients with different doses of ponatinib, finding that the optimal benefit/risk outcomes were achieved with a starting dose of 45 mg and decreased to 15 mg upon response.
Article
Medicine, General & Internal
Mengyan Wang, Yu Xue, Fang Du, Lili Ma, Liang-jing Lu, Lindi Jiang, Yi-Li Tao, Chengde Yang, Hui Shi, Honglei Liu, Xiaobing Cheng, Junna Ye, Yutong Su, Dongbao Zhao, Sheng-Ming Dai, Jialin Teng, Qiongyi Hu
Summary: This study compares the outcomes of continuing, reducing the dose, or withdrawing tofacitinib in patients with stable disease control in the treatment of rheumatoid arthritis. The results show that after a 6-month maintenance period, the withdrawal group had poorer disease control, while the continuation and dose reduction groups maintained a better state.
CHINESE MEDICAL JOURNAL
(2023)
Article
Oncology
Matthias Fischer, Lucas Moreno, David S. Ziegler, Lynley Marshall, C. Michel Zwaan, Meredith S. Irwin, Michela Casanova, Constantino Sabado, Beate Wulff, Mario Stegert, Luojun Wang, Felipe K. Hurtado, Fabrice Branle, Birgit Geoerger, Johannes H. Schulte
Summary: This study investigated the safety, pharmacokinetics, and efficacy of ceritinib in paediatric patients with ALK-positive malignancies. Results showed that the recommended dose for paediatric patients with ALK-positive malignancies is 500 mg/m(2) of ceritinib, which demonstrated promising antitumor activity.
Article
Critical Care Medicine
Robert S. Wallis, Sibuse Ginindza, Trevor Beattie, Nishanee Arjun, Modulakgotla Sebe, Morongwe Likoti, Vinodh A. Edward, Mohammed Rassool, Khatija Ahmed, Katherine Fielding, Bintou A. Ahidjo, Mboyo D. T. Vangu, Gavin Churchyard
Summary: This study conducted a phase 2 clinical trial in South Africa to evaluate the safety and preliminary efficacy of four host-directed therapies for tuberculosis. The results showed that CC-11050 and everolimus as adjunctive therapies have the potential benefits for tuberculosis patients, increasing the recovery of FEV1.
LANCET RESPIRATORY MEDICINE
(2021)
Article
Medicine, General & Internal
Ana Belen Rivas, Amanda Lopez-Picado, Valentina Calamia, Ester Carreno, Lidia Cocho, Miguel Cordero-Coma, Alex Fonollosa, Felix M. Francisco Hernandez, Angel Garcia-Aparicio, Javier Garcia-Gonzalez, Jose Juan Mondejar, Leticia Lojo-Oliveira, Lluci Martinez-Costa, Santiago Munoz, Diana Peiteado, Jose Antonio Pinto, Beatriz Rodriguez-Lozano, Esperanza Pato, David Diaz-Valle, Elena Molina, Luis Alberto Tebar, Luis Rodriguez-Rodriguez
Summary: Non-infectious uveitis is a group of conditions that can lead to vision loss and disability. This study aims to compare the efficacy, safety, and cost-effectiveness of different treatment strategies for non-infectious non-anterior uveitis, and develop prediction models using genetic and proteomic biomarkers to identify different treatment responses.
Article
Rheumatology
Luis F. Perez-Garcia, Esther Roder, Hieronymus T. W. Smeele, Robbert Goekoop, Johanna M. W. Hazes, Marc R. Kok, Ilja Tchetverikov, Annette Van der Helm-van Mil, Jos van der Kaap, Petra Kok, Bouwe P. Krijthe, Radboud J. E. M. Dolhain
Summary: This study described the pregnancy outcomes of partners of men diagnosed with inflammatory arthritis (IA) and found that pregnancies conceived after the diagnosis of IA had a higher rate of miscarriage, which continued to be present even after adjusting for confounders. However, the overall rate of miscarriage reported in the study could be comparable to previously reported population estimates.
Article
Rheumatology
Jeffrey R. Curtis, Kunihiro Yamaoka, Yi-Hsing Chen, Deepak L. Bhatt, Levent M. Gunay, Naonobu Sugiyama, Carol A. Connell, Cunshan Wang, Joseph Wu, Sujatha Menon, Ivana Vranic, Juan J. Gomez-Reino
Summary: This study evaluated malignancies and their associations with baseline risk factors and cardiovascular risk scores in patients with rheumatoid arthritis (RA) treated with tofacitinib and tumour necrosis factor inhibitors (TNFi). The results showed that the risk of malignancies was increased with tofacitinib compared to TNFi, and the highest incidence was observed in patients with a history of atherosclerotic cardiovascular disease (HxASCVD) or increasing cardiovascular risk.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Ruediger B. Mueller, Hendrik Schulze-Koops, Daniel E. Furst, Stanley B. Cohen, Kenneth Kwok, Lisy Wang, Tim Killeen, Johannes von Kempis
Summary: This analysis assessed the impact of dose switching on efficacy and safety in rheumatoid arthritis patients receiving tofacitinib. It found that increasing the dose from 5 to 10 mg improved efficacy, while decreasing the dose from 10 to 5 mg did not affect efficacy. Dose switching in either direction did not impact safety.
CLINICAL RHEUMATOLOGY
(2022)
Article
Rheumatology
Satoshi Kubo, Yusuke Miyazaki, Koichi Amano, Kiyoshi Matsui, Hideto Kameda, Yoshino Inoue, Shingo Nakayamada, Takehisa Ogura, Yuko Kaneko, Kunihiro Yamaoka, Yoshiya Tanaka
Summary: This study aimed to investigate sustained remission following discontinuation of tofacitinib in patients with rheumatoid arthritis. The study found that only 29.2% of patients remained in remission after discontinuation of tofacitinib, while 50% of patients sustained remission after discontinuing MTX. The study also found that 71.4% of patients who relapsed after tofacitinib discontinuation achieved remission with resumption of tofacitinib.
Article
Medicine, General & Internal
Dario Bruno, Anna Laura Fedele, Barbara Tolusso, Angelina Barini, Luca Petricca, Clara Di Mario, Antonella Barini, Luisa Mirone, Gianfranco Ferraccioli, Stefano Alivernini, Elisa Gremese
Summary: The study revealed that bone erosions in rheumatoid arthritis patients are closely associated with systemic bone loss, with early osteoporotic patients being more prone to erosions. Disease activity score and osteopenia/osteoporosis status were identified as independent factors of erosiveness.
FRONTIERS IN MEDICINE
(2021)
Article
Medicine, General & Internal
Charlotte E. Coles, Joanne S. Haviland, Anna M. Kirby, Clare L. Griffin, Mark A. Sydenham, Jenny C. Titley, Indrani Bhattacharya, A. Murray Brunt, H. Y. Charlie Chan, Ellen M. Donovan, David J. Eaton, Marie Emson, Penny Hopwood, Monica L. Jefford, Sara Lightowlers, Elinor J. Sawyer, Isabel Syndikus, Yat M. Tsang, Nicola Twyman, John R. Yarnold, Judith M. Bliss, IMPORT Trial Management Grp
Summary: IMPORT HIGH trial compared the efficacy and toxicity of simultaneous integrated boost and sequential boost radiotherapy regimens. The results showed that regardless of the boost sequencing, the 5-year incidence of ipsilateral breast tumor relapse was lower than the expected 5%. Simultaneous integrated boost regimen reduced patient visits and had potential benefits.
Article
Medicine, General & Internal
Barham K. Abu Dayyeh, Daniel B. Maselli, Babusai Rapaka, Thomas Lavin, Mark Noar, Hisham Hussan, Christopher G. Chapman, Violeta Popov, Pichamol Jirapinyo, Andres Acosta, Eric J. Vargas, Andrew C. Storm, Fateh Bazerbachi, Marvin Ryou, Matthew French, Sabrena Noria, Daniel Molina, Christopher C. Thompson
Summary: The study on obese adults showed that using an adjustable intragastric balloon combined with lifestyle intervention can significantly reduce weight and maintain it for 6 months. Adjusting the balloon volume allows for personalized therapy, maximizing weight loss and tolerance.
Article
Dermatology
D. Wilsmann-Theis, C. Kromer, S. Gerdes, C. Linker, N. Magnolo, R. Sabat, K. Reich, R. Mossner
Summary: The study investigated the efficacy of apremilast in treating palmoplantar pustulosis (PPP) and found that 20 weeks of oral treatment resulted in significant improvement in both objective and subjective disease parameters, with minimal adverse events.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Dermatology
Renaud Felten, Dan Lipsker, Jean Sibilia, Francois Chasset, Laurent Arnaud
Summary: The term lupus has been used since the Middle Ages to refer to several diseases characterized by ulcerous lesions. In the 19th century, a distinction between different types of lupus emerged, and the systemic nature of the disease was recognized. Modern treatments such as glucocorticoids, hydroxychloroquine, and immunosuppressive agents emerged in the second half of the 20th century. In the 21st century, there has been a deeper understanding of the disease's pathogenesis and the development of biologic and targeted treatments.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Medicine, General & Internal
Thierry Pelaccia, Jean Sibilia, Elodie Fels, Lucas Gauer, Audrey Musanda, Francois Severac, Milena Abbiati
Summary: The COVID-19 pandemic has led to increased staffing needs in emergency departments, sparking debates on whether medical students should assist. A study conducted at Strasbourg Medical School found that anxiety levels among medical students were higher in 2020 compared to 2018, especially for those who chose not to return to clinical settings. Gender and perceived clinical activity personal conditions were identified as main factors associated with anxiety, while working in clinical settings during the outbreak was not a risk factor for anxiety, suggesting it as an active coping strategy.
INTERNAL AND EMERGENCY MEDICINE
(2021)
Article
Rheumatology
Marc Scherlinger, Johanna Lutz, Gael Galli, Christophe Richez, Jacques-Eric Gottenberg, Jean Sibilia, Laurent Arnaud, Patrick Blanco, Thierry Schaeverbeke, Emmanuel Chatelus, Marie-Elise Truchetet
Summary: This study found significant differences in clinical characteristics and prognosis in patients with systemic sclerosis who have concomitant autoimmune diseases. Patients with overlap SgS/SSc had a higher risk of mortality, while those with RA/SSc received more medication treatments.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2021)
Article
Rheumatology
Nadege Cordel, Celine Derambure, Sophie Coutant, Xavier Mariette, Denis Jullien, Sebastien Debarbieux, Olivier Chosidow, Alain Meyer, Didier Bessis, Pascal Joly, Alexis Mathian, Herve Levesque, Jean-Christophe Sabourin, Isabelle Tournier, Olivier Boyer
Summary: This study deep sequenced the TRIM33 gene in tumours from patients with cancer-associated anti-TIF1 gamma autoantibody-positive DM, identifying potential somatic variants. The results support the hypothesis of a role of TRIM33 gene mutations in the pathophysiology of anti-TIF1 gamma autoantibody-positive DM, consistent with previous reports.
Article
Rheumatology
Renaud Felten, Maxime Dubois, Manuel F. Ugarte-Gil, Aurore Chaudier, Lou Kawka, Hugo Bergier, Charlotte Costecalde, Luc Pijnenburg, Jeremy Fort, Emmanuel Chatelus, Christelle Sordet, Rose-Marie Javier, Jacques-Eric Gottenberg, Jean Sibilia, Yurilis J. Fuentes-Silva, Laurent Arnaud
Summary: The study identified three distinct clusters of AIIRD patients with different attitudes towards SARS-CoV-2 vaccination: voluntary, hesitant, and suspicious. Differences in vaccination willingness among these clusters were mainly related to specific concerns about vaccination, rather than fear of COVID-19 infection or frailty. This research may help improve communication strategies to increase COVID-19 vaccine coverage among AIIRD patients.
Article
Rheumatology
Bernard Combe, Nathalie Rincheval, Francis Berenbaum, Patrick Boumier, Alain Cantagrel, Philippe Dieude, Maxime Dougados, Bruno Fautrel, Rene-Marc Flipo, Philippe Goupille, Xavier Mariette, Alain Saraux, Thierry Schaeverbeke, Jean Sibilia, Olivier Vittecoq, Jean-Pierre Daures
Summary: The 10-year outcome of patients with early rheumatoid arthritis (RA) from the ESPOIR cohort showed favorable results, with a significant proportion achieving remission and good control of symptoms. However, some patients developed new comorbidities over the follow-up period, and positivity for anti-citrullinated peptides antibodies (ACPA) was confirmed as a strong predictor of long-term outcome.
Article
Rheumatology
Dan Levy, Benoit Nespola, Margherita Giannini, Renaud Felten, Francois Severac, Coralie Varoquier, Marina Rinagel, Anne-Sophie Korganow, Thierry Martin, Vincent Poindron, Francois Maurier, Haitham Chereih, Bastien Bouldoires, Baptiste Hervier, Cedric Lenormand, Emmanuel Chatelus, Bernard Geny, Jean Sibilia, Laurent Arnaud, Jacques-Eric Gottenberg, Alain Meyer
Summary: In myositis patients, Sjogren's syndrome is associated with inclusion body myositis and anti-cN1A antibodies, independently of the IBM diagnosis. As a consequence, anti-cN1A has limited specificity for IBM in myositis patients with Sjogren's syndrome.
Letter
Rheumatology
Renaud Felten, Pierre-Marie Duret, Elodie Bauer, Nathanael Sedmak, Julien H. Djossou, Massiva Bensalem, Marc Ardizzone, Marion Geoffroy, Angelique Fan, Marion Couderc, Jean Hugues Salmon, Laurent Messer, Rose-Marie Javier, Alain Meyer, Emmanuel Chatelus, Christelle Sordet, Luc Pijnenburg, Jeremy Fort, Marina Rinagel, Julia Walther, Cassandre Fabre, Laurent Arnaud, Jean Sibilia, Nicolas Meyer, Francis Berenbaum, Isabelle Chary-Valckenaere, Martin Soubrier, Jeremie Sellam, Jacques-Eric Gottenberg
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
L. Widawski, T. Fabacher, L. Spielmann, J. E. Gottenberg, J. Sibilia, P. M. Duret, L. Messer, R. Felten
Summary: This study aimed to investigate the effects of hyperuricemia on the clinical presentation, severity, and associated comorbidities of psoriatic arthritis (PsA). The results showed that patients with hyperuricemic PsA had a higher prevalence of male gender, higher body mass index, and more comorbidities compared to patients with normal uric acid levels. Hyperuricemic PsA was associated with older age at onset, more polyarticular and destructive joint involvement. Additionally, hyperuricemic PsA patients had a poorer response to treatment and more peripheral joint damage than normo-uricemic patients.
CLINICAL RHEUMATOLOGY
(2022)
Article
Cell Biology
Raphael Carapito, Richard Li, Julie Helms, Christine Carapito, Sharvari Gujja, Veronique Rolli, Raony Guimaraes, Jose Malagon-Lopez, Perrine Spinnhirny, Alexandre Lederle, Razieh Mohseninia, Aurelie Hirschler, Leslie Muller, Paul Bastard, Adrian Gervais, Qian Zhang, Francois Danion, Yvon Ruch, Maleka Schenck, Olivier Collange, Thien-Nga Chamaraux-Tran, Anne Molitor, Angelique Pichot, Alice Bernard, Ouria Tahar, Sabrina Bibi-Triki, Haiguo Wu, Nicodeme Paul, Sylvain Mayeur, Annabel Larnicol, Geraldine Laumond, Julia Frappier, Sylvie Schmidt, Antoine Hanauer, Cecile Macquin, Tristan Stemmelen, Michael Simons, Xavier Mariette, Olivier Hermine, Samira Fafi-Kremer, Bernard Goichot, Bernard Drenou, Khaldoun Kuteifan, Julien Pottecher, Paul-Michel Mertes, Shweta Kailasan, M. Javad Aman, Elisa Pin, Peter Nilsson, Anne Thomas, Alain Viari, Damien Sanlaville, Francis Schneider, Jean Sibilia, Pierre-Louis Tharaux, Jean-Laurent Casanova, Yves Hansmann, Daniel Lidar, Mirjana Radosavljevic, Jeffrey R. Gulcher, Ferhat Meziani, Christiane Moog, Thomas W. Chittenden, Seiamak Bahram
Summary: In this study, multi-omics analysis and artificial intelligence were used to examine the differences in biological factors between critical and non-critical COVID-19 patients in a young and otherwise healthy cohort. The study identified ADAM9 as a driver of disease severity and a potential therapeutic target.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Immunology
Marc Scherlinger, Luc Pijnenburg, Emmanuel Chatelus, Laurent Arnaud, Jacques-Eric Gottenberg, Jean Sibilia, Renaud Felten
Summary: This study suggests that SARS-CoV-2 vaccination is well tolerated and immunogenic in the majority of patients with long-COVID or post-acute sequelae of COVID-19 (PASC). Disseminating these reassuring data might prove crucial to increasing vaccine coverage in patients with PASC.
Editorial Material
Rheumatology
Renaud Felten, Floriane Gallais, Cedric Schleiss, Emmanuel Chatelus, Rose-Marie Javier, Luc Pijnenburg, Christelle Sordet, Jean Sibilia, Laurent Arnaud, Samira Fafi-Kremer, Jacques-Eric Gottenberg
LANCET RHEUMATOLOGY
(2022)
Editorial Material
Rheumatology
Jean-Marie Berthelot, Frederic Liote, Jean Sibilia
Article
Rheumatology
Arthur Petitdemange, Renaud Felten, Jean Sibilia, Thierry Martin, Laurent Arnaud
Summary: The study reveals significant heterogeneity in antimalarial agent prescription among physicians treating lupus, with key unmet needs identified regarding this treatment approach. This highlights the importance of developing more comprehensive recommendations and promoting dissemination among healthcare providers.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
(2021)
Article
Rheumatology
A. Mariotte, L. Bernardi, C. Macquin, A. DeCauwer, I Kotova, S. Blueml, D. Noel, A. Scanu, L. Punzi, R. Carapitou, J. Sibilia, S. Bahram, P. Georgel
Summary: The study found marked overproduction of sMICA in the synovial fluid of patients with rheumatoid arthritis. Mouse studies demonstrated the complex transcriptional regulation of Nkg2d ligands encoding genes depending on the inflammatory setting and microenvironment. Quantification of sMICA could be an interesting biomarker for identifying acute inflammation in rheumatoid arthritis patients where classical markers are undetectable.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)